ATE432081T1 - Malaria-vakzine - Google Patents

Malaria-vakzine

Info

Publication number
ATE432081T1
ATE432081T1 AT03810941T AT03810941T ATE432081T1 AT E432081 T1 ATE432081 T1 AT E432081T1 AT 03810941 T AT03810941 T AT 03810941T AT 03810941 T AT03810941 T AT 03810941T AT E432081 T1 ATE432081 T1 AT E432081T1
Authority
AT
Austria
Prior art keywords
protein
hybrid
glutamate
antibody response
individual
Prior art date
Application number
AT03810941T
Other languages
English (en)
Inventor
Michael Theisen
Soren Jepsen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE432081T1 publication Critical patent/ATE432081T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03810941T 2002-11-12 2003-11-06 Malaria-vakzine ATE432081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine

Publications (1)

Publication Number Publication Date
ATE432081T1 true ATE432081T1 (de) 2009-06-15

Family

ID=32313776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810941T ATE432081T1 (de) 2002-11-12 2003-11-06 Malaria-vakzine

Country Status (13)

Country Link
US (2) US7749507B2 (de)
EP (1) EP1567189B1 (de)
JP (1) JP4573773B2 (de)
CN (1) CN1741815B (de)
AT (1) ATE432081T1 (de)
AU (1) AU2003275949B2 (de)
BR (1) BR0315205A (de)
CA (1) CA2505724C (de)
DE (1) DE60327801D1 (de)
DK (2) DK200201741A (de)
ES (1) ES2326415T3 (de)
WO (1) WO2004043488A1 (de)
ZA (1) ZA200504415B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
SG175846A1 (en) * 2009-05-05 2011-12-29 Cadila Healthcare Ltd Combined measles-malaria vaccine
CN102471361B (zh) 2009-07-15 2016-06-01 不列颠哥伦比亚大学 作为神经氨酸酶抑制剂的2,3-氟化糖苷及其作为抗病毒药物的用途
EP2385107B1 (de) * 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
WO2013050034A1 (en) * 2011-10-04 2013-04-11 Statens Serum Institut Production of a cysteine rich protein
WO2013082394A1 (en) * 2011-11-30 2013-06-06 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
US9637465B2 (en) 2012-01-19 2017-05-02 The University Of British Columbia 3′ Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
AU2017268453A1 (en) 2016-05-19 2019-01-17 Ahmed S.I. Aly Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
CA3031399A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
WO1990002811A1 (en) * 1988-09-16 1990-03-22 Statens Seruminstitut A malaria antigen
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
WO2000050077A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
AU2002304480A1 (en) * 2001-05-16 2002-11-25 Institut Pasteur Plasmodium falciparum antigens and vaccine and diagnostic uses thereof
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
US20110020387A1 (en) 2011-01-27
EP1567189A1 (de) 2005-08-31
CA2505724C (en) 2015-06-30
DE60327801D1 (de) 2009-07-09
HK1080754A1 (en) 2006-05-04
DK1567189T3 (da) 2009-09-14
BR0315205A (pt) 2005-08-16
ES2326415T3 (es) 2009-10-09
CN1741815B (zh) 2010-05-26
US7749507B2 (en) 2010-07-06
JP4573773B2 (ja) 2010-11-04
CN1741815A (zh) 2006-03-01
JP2006512926A (ja) 2006-04-20
DK200201741A (da) 2003-09-16
AU2003275949B2 (en) 2008-06-05
WO2004043488A1 (en) 2004-05-27
US20060024324A1 (en) 2006-02-02
AU2003275949A1 (en) 2004-06-03
CA2505724A1 (en) 2004-05-27
ZA200504415B (en) 2006-03-29
EP1567189B1 (de) 2009-05-27

Similar Documents

Publication Publication Date Title
DK1567189T3 (da) Malariavaccine
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
EP1490483A4 (de) In-vivo-einbau von nicht in der natur vorkommenden aminosäuren
ATE412433T1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
EP4585260A3 (de) Verfahren zur behandlung von hämophilie a
FR2744724B1 (fr) Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
DE60038567D1 (de) Modifiziertes gp100 und dessen verwendung
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
ATE547529T1 (de) Materialien und verfahren im zusammenhang mit verbesserten impfstrategien
ATE399180T1 (de) Rekombinante polypeptide
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
ATE332380T1 (de) Materialen und verfahren mit bezug auf immunantworten gegen fusionsproteine
ATE448793T1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
WO2004044167A3 (en) Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
DE60216523D1 (de) Herstellung und verwendung von mit verzweigten aminosäuren angereicherten sojaproteinhydrolysaten
ATE139537T1 (de) Gen zum kodieren eines antigens gegen menschlichen malaria impfstoff
WO2004033705A3 (en) Viral interferon antagonists and uses therefor
EP1802778A4 (de) Hcv-antigene zur mehrfachen epitopfusion mit modifizierten proteolytischen spaltungsorten und verwendungen davon
GB0220805D0 (en) Peptide monomers and protein structures
AU2003282159A8 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
DE50111910D1 (de) Verfahren zur synthese von peptiden, peptidmimetika und proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties